Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Pozycja w akcjach #2251
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Cena akcji
$108.61
Kapitalizacja rynkowa
$8.93B
Zmiana (1 dzień)
3.65%
Zmiana (1 rok)
81.52%
Kraj
US
Handel Kymera Therapeutics, Inc. (KYMR)

Kategoria

Healthcare
Historia dywidend dla Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (symbol giełdowy: KYMR) wypłaciła łącznie 0 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): 0.00
Wskaźnik dywidendy (TTM): 0
Wypłaty dywidend dla Kymera Therapeutics, Inc. (KYMR) od 2026 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
Za mało danych dla podanych dat.
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
Za mało danych dla podanych dat.
Wypłaty dywidend firm podobnych lub konkurencyjnych
Firma Liczba wypłat dywidend Kraj
0.00%
US
0.00%
US
64.00%
AU
0.00%
CH
0.00%
NL